Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, announces its results for the year...
Read MoreSareum Holdings plc (AIM: SAR), the specialised small molecule drug development business, announces its results for the year ended 30 June 2019 and provides an update of significant post-period events....
Read MoreSareum Holdings plc (AIM: SAR), the specialised small molecule drug development business, provides the following trading update ahead of its full year results for the year ended 30 June 2019....
Read MoreSareum Holdings PLC, the specialist small molecule drug development business announced on 25 June 2019 the launch of a fundraising comprising a placing by Hybridan LLP in conjunction with an offer...
Read MoreSareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, announces its half-yearly results for the six months ended 31 December 2018 and provides an update of...
Read MoreSareum Holdings plc (AIM: SAR), the specialist in small molecule drug development, announces its results for the year ended 30 June 2018 and provides an update of significant post-period events....
Read MoreSareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, announced that it has regained worldwide rights to preclinical-stage small molecule inhibitors of Aurora and FLT3 kinases...
Read More